Funded Biotechnology Startups in Edinburgh
Edinburgh's biotechnology sector has drawn consistent early-stage investment across the 18 rounds shown here, spanning July 2021 to July 2025.
Edinburgh's biotechnology sector has drawn consistent early-stage investment across the 18 rounds shown here, spanning July 2021 to July 2025. Rounds range from Medannex's $400K close in July 2024 to the $11M raises by Wobble Genomics and Cumulus Oncology, both in early 2024. The sub-sectors vary considerably: therapeutics companies such as Lario Therapeutics, Kynos Therapeutics, and Cumulus Oncology sit alongside genomics plays like Concinnity Genetics and Wobble Genomics, as well as more unusual angles in renewable bio-feedstocks (Celtic Renewables) and alternative proteins (Nandi Proteins).
Seed rounds account for six of the 18 closes, while the majority carry a "Series Unknown" label — a common pattern for early Scottish biotech raises that may blend grant co-investment with equity. Activity is heavily concentrated in 2024, which accounts for ten of the 18 rounds, including Calcivis ($6M, April 2024) and Lario Therapeutics ($6M, July 2024). The most recent close on record is EnteroBiotix ($1M, July 2025).
Most recent rounds
18 shownRelated listings
Frequently asked
What are the largest rounds among Edinburgh biotech companies in this dataset?
Wobble Genomics and Cumulus Oncology each raised $11M — Wobble Genomics in March 2024 and Cumulus Oncology in January 2024. The next tier includes Kynos Therapeutics ($9M, April 2022) and three companies that each raised $6M: Lario Therapeutics (July 2024), Calcivis (April 2024), and Macomics (July 2021).
How active was Edinburgh biotech fundraising in 2024?
Ten of the 18 rounds shown closed during 2024, ranging from Cumulus Oncology's $11M in January to Concinnity Genetics' $4M Seed in December. That volume contrasts sharply with 2023 and 2022, which each account for only two rounds in this dataset.
What round stages appear most often, and is the stage data reliable?
The "Series Unknown" label covers 11 of the 18 rows, which is common in early Scottish biotech where grant co-investment or convertible instruments can obscure formal stage classification. Six rounds are labeled Seed — including Cumulus Oncology ($11M) and Kynos Therapeutics ($9M) — showing that Seed here does not necessarily mean small. One round, Wobble Genomics ($11M, March 2024), carries no stage label at all.
What sub-sectors do these Edinburgh biotech companies cover?
Company names point to a spread beyond core therapeutics: Wobble Genomics and Concinnity Genetics are in genomics, Celtic Renewables and Green Bioactives target bio-renewable chemicals, Nandi Proteins addresses alternative proteins, and Calcivis sits in oral health diagnostics. Straight therapeutics and oncology plays — Lario Therapeutics, Kynos Therapeutics, Cumulus Oncology — are present but not dominant across the 18 companies.
How common are sub-$1M closes in this segment?
Four of the 18 rounds fall below $1M: Medannex ($400K, July 2024), Bioliberty ($440K, December 2023), Dyneval ($630K, January 2025), and Nandi Proteins ($660K, August 2024). These small closes likely reflect non-dilutive or mixed grant-equity structures rather than standard pre-seed equity rounds.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.